Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort

Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort

Background and Aims: The multikinase inhibitor cabozantinib has been approved for hepatocellular carcinoma (HCC) previously treated with sorafenib. We report safety and efficacy data of an international, multicenter, real-life cohort of patients with advanced HCC treated with cabozantinib. Methods:...

Full description

Bibliographic Details
Main Authors: Fabian Finkelmeier, Bernhard Scheiner, Catherine Leyh, Jan Best, Thorben Wilhelm Fründt, Carolin Czauderna, Alica Beutel, Dominik Bettinger, Johannes Weiß, Tobias Meischl, Fabian Kütting, Dirk-Thomas Waldschmidt, Pompilia Radu, Michael Schultheiß, Kai-Henrik Peiffer, Thomas J. Ettrich, Arndt Weinmann, Henning Wege, Marino Venerito, Jean-Francois Dufour, Christian M. Lange, Matthias Pinter, Oliver Waidmann
Format: Article
Language:English
Published: Karger Publishers 2021-06-01
Series:Liver Cancer
Subjects:
hepatocellular carcinoma
cabozantinib
Online Access:https://www.karger.com/Article/FullText/515490

Internet

https://www.karger.com/Article/FullText/515490

Similar Items